Tigecycline is a glycylcycline antibiotic, first clinically available drug in a new class of antibiotics called the glycylcyclines. Tigecycline is bacteriostatic and is a protein synthesis inhibitor by binding to the 30S ribosomal subunit of bacteria and thereby blocking entry of Aminoacyl-tRNA into the A site of the ribosome during prokaryotic translation. Tigecycline is given intravenously and has activity against a variety of Gram-positive and Gram-negative bacterial pathogens, many of which are resistant to existing antibiotics.
|Product||Active Ingredient(s)||Strength||Features||Dosage Form|
• Tigecycline provided clinical cure rate comparable to:
> Combination of vancomycin aztreonam in cSSSI
> Imipenem/cilastatin in cIAI
> Levofloxacin in CABP
• Tigecycline had a low overall discontinuation rate due to adverse events in clinical studies